Glenmark Pharmaceuticals Limited — Q1FY27 earnings call summary

Filed 05 August 2026 · Official transcript

Gross margin impacted by geopolitical cost pressures; full-year margin guidance maintained at 21-22%
India business growth guidance 12-15% with volume-led growth and new product launches
Key priorities: US respiratory launches in H2 FY27, oncology launches Aumolertinib, Trastuzumab Rezetecan, envafolimab
Consolidated revenue grew 23.1% Y-o-Y to INR40.2bn in Q1 FY27; base business up 18% excluding deferred income
R&D spend around INR289cr in Q1; guided at 7-8% of sales; IGI pipeline progressing with multiple clinical trials
Litigation provisions mostly done; no significant incremental cash outflows expected
North America revenue up 41.1% Y-o-Y; core business growth 19.8%; 9 new product launches including respiratory
India formulation sales grew 15.5% Y-o-Y; strong growth in dermatology, respiratory, cardiac, oncology